<DOC>
	<DOCNO>NCT01924091</DOCNO>
	<brief_summary>To compare drug concentration vaginal fluid , genital tissue , blood</brief_summary>
	<brief_title>PK/PD Single Dose Dapivirine Vaginal Film</brief_title>
	<detailed_description />
	<criteria>1 . 18 year age old history receptive vaginal intercourse . 2 . HIV negative EIA within 28 day enrollment . 3 . Understand agree local STI reporting requirement . 4 . Able willing provide write informed consent take part study . 5 . Able willing provide adequate information locator purpose . 6 . Availability return study visit , bar unforeseen circumstance . 7 . Availability return second formulation dose time subject 's menstrual cycle first formulation administer , least 10 day menses . 8 . Willing abstain vaginal intercourse insertion anything ( e.g. , drug , vaginal douche , sex toy ) vagina 72 hour study product exposure , 7 day follow vaginal sampling procedure . 9 . Willingness partner ( ) use condom ( must contain Nonoxynol9 ) duration study . 10 . Agree participate research study involve drug and/or medical device . 11 . Negative qualitative urine pregnancy test . 12 . Per participant report , use effective method contraception enrollment ; hormonal method ( except vaginal ring ) use continuously past 30 day ; intrauterine device ( IUD [ copper hormonal ] insert least 30 day prior enrollment ) ; female sterilization ; abstinent sexual activity male partner past 30 day ; sexual activity vasectomize partner ; willingness use effective method contraception completion final schedule study visit enrol . 13 . Willingness remain research unit 24 hour two dose day , 1 . Current sexual partner know participant HIV seropositive . 2 . Individuals , history , engage condomless intercourse HIVinfected partner , partner unknown HIV serostatus , woman exchange sex money , shelter , gift . 3 . Active sexually transmit infection document treatment sexually transmit infection include , limited : chlamydia , gonorrhea , syphilis , trichomonas , cervicitis PID within 6 month prior enrollment . 4 . Known history genital HSV ( diagnose either clinical laboratory test ) . 5 . Symptomatic vaginal candidiasis bacterial vaginosis . 6 . Undiagnosed irregular uterine bleed 7 . Pathology female genital tract , judgment investigator might increase risk study research participant . 8 . Individuals status post hysterectomy . 9 . History cervicovaginal procedure ( i.e . colposcopy cervical biopsy ) within past 2 month . Individuals history cone biopsy extensive loop electrosurgical excision procedure ( LEEP ) , judgment investigator may affect permeability assessment . 10 . Any known primary secondary urogenital malformation , assessment investigator may interfere intend urine collection PK study . 11 . Use vaginally administer medication within 4 week enrollment 12 . Any active urinary tract infection 13 . By history , subject irregular menstrual cycle . 14 . At screening : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 1.5 X site laboratory ULN ( upper limit normal ) Hemoglobin le 10.0 g/dL Platelet count le 100,000/mm3 Other safety test outside normal range judgment investigator may interfere conduct study . Positive finding urinalysis clinically significant opinion investigator 15 . Estimated creatinine clearance &lt; 60 ml/min base establish nomograms 16 . Recent history ( past 6 month ) injection drug use , level alcohol use , judgement Investigator Record , may interfere conduct study . 17 . Unwillingness refrain aspirin NSAIDs product use one week prior one week post study procedure . 18 . Use warfarin heparin . 19 . Use systemic immunomodulatory medication within 4 week enrollment . 20 . Use product contain nonoxynol9 within 4 week enrollment . 21 . Use investigational product within 4 week enrollment . 22 . Any medical condition deem safe participation investigator . 23 . Any individual actively breast feed . 24 . Postmenopausal define 12 month amenorrhea .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>